Estramustine Phosphate Therapy in Carcinoma of the Prostate

Abstract

Estramustine phosphate in the treatment of prostatic carcinoma was introduced in 1966. The substance is an estradiol-17-β-phosphate which is esterified with nor nitrogen mustard as a carbamate. It has become known under the trade name Estracyt.